Table 4.

Comparison of work productivity outcomes, presented by level of severity in respondents with atopic dermatitis (AD) and regions and total population

Outcome variable	AD severity (PO‐SCORAD)
	Mild		Moderate		Severe		Severe 1		Severe 2		Severe 3+
	PO‐SCORAD < 25		PO‐SCORAD 25–50		PO‐SCORAD > 50		PO‐SCORAD 51–60		PO‐SCORAD 61–70		PO‐SCORAD 71+
	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD
Absenteeism (%)
Europe	48	2·0 ± 9·9	255	5·1 ± 15·1	87	10·9 ± 18·6	43	7·0 ± 13·7	31	12·1 ± 19·0	13	21·1 ± 27·4
U.S.A.	22	2·4 ± 10·7	208	3·2 ± 12·4	81	9·7 ± 20·4	47	6·1 ± 15·7	23	16·6 ± 28·1	11	10·5 ± 17·1
Total	70	2·1 ± 10·1	463	4·2 ± 14·0	168	10·3 ± 19·5	90	6·5 ± 14·7	54	14·0 ± 23·2	24	16·3 ± 23·4
Presenteeism (%)
Europe	48	2·9 ± 7·7	255	22·1 ± 24·2	87	43·5 ± 30·2	43	38·4 ± 28·9	31	45·8 ± 29·6	13	54·6 ± 34·3
U.S.A.	22	6·4 ± 12·9	208	22·0 ± 22·9	81	43·3 ± 26·7	47	41·3 ± 26·3	23	47·7 ± 28·1	11	42·7 ± 26·9
Total	70	4·0 ± 9·7	463	22·0 ± 23·6	168	43·4 ± 28·5	90	39·9 ± 27·4	54	46·6 ± 28·8	24	49·2 ± 31·1
Overall work impairment (%)
Europe	48	4·8 ± 12·7	255	24·4 ± 27·4	87	47·6 ± 30·7	43	41·2 ± 29·4	31	51·6 ± 28·6	13	59·0 ± 36·8
U.S.A.	22	8·7 ± 15·9	208	23·7 ± 25·1	81	47·4 ± 28·7	47	44·1 ± 27·0	23	54·8 ± 31·5	11	46·3 ± 29·7
Total	70	6·0 ± 13·8	463	24·1 ± 26·4	168	47·5 ± 29·7	90	42·7 ± 28·1	54	53·0 ± 29·6	24	53·2 ± 33·6
Activity impairment (%)
Europe	84	6·6 ± 12·0	413	26·3 ± 24·4	135	52·4 ± 27·4	62	44·2 ± 24·4	46	52·8 ± 24·9	27	70·4 ± 30·2
U.S.A.	50	12·0 ± 18·3	412	24·8 ± 24·8	138	52·5 ± 26·7	79	47·5 ± 25·1	37	54·9 ± 29·5	22	66·4 ± 22·8
Total	134	8·6 ± 14·8	825	25·5 ± 24·6	273	52·4 ± 27·0	141	46·0 ± 24·8	83	53·7 ± 26·9	49	68·6 ± 26·9

PO‐SCORAD, Patient‐Oriented Scoring Atopic Dermatitis. Europe represents France, Germany and the U.K.